Production of Induced Pluripotent Stem Cell-Derived Red Blood Cells.

Hyun Hyung An, Giulia Pavani, Stella T Chou

Abstract read

In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hyun Hyung AnDepartment of Cell and Molecular Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

Giulia PavaniDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

Stella T ChouDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. chous@chop.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Red blood cell (RBC) transfusion is one of the most common medical treatments, with over 10 million units transfused per year in the United States alone. One complication following transfusion is red cell alloimmunization, the production of antibodies to foreign proteins on donor RBCs. Identifying compatible RBC units for alloimmunized patients may be challenging due to the lack of specific RBC reagents with uncommon or rare RBC antigen phenotypes that are needed to identify the precise antibody target. Human induced pluripotent stem cells (iPSCs) represent a renewable source of cells to generate specialized RBCs by reprogramming rare donor cells or by gene editing iPSCs. These iPSCs can provide an unlimited supply of RBCs with unique antigen expression profiles. Here, we outline protocols to generate developmentally primitive (embryonic) and definitive (fetal) RBCs from iPSCs, and methods to perform antibody identification using iPSC-derived RBCs as reagent cells in gel agglutination assays commonly used by blood banks and reference immunohematology laboratories.

Indexed as

Cell Culture TechniquesErythrocytesInduced Pluripotent Stem CellsCell DifferentiationHumansAntibody identificationHematopoietic progenitor cellInduced pluripotent stem cellsRed blood cellRed blood cell reagents

Identifiers

PMID42681434

DOI10.1038/nrm.2016.127

What Socratic holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.